SAN Stock Overview
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally.
No risks detected for SAN from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||€102.78|
|52 Week High||€105.18|
|52 Week Low||€77.10|
|1 Month Change||4.12%|
|3 Month Change||3.99%|
|1 Year Change||32.71%|
|3 Year Change||19.26%|
|5 Year Change||33.60%|
|Change since IPO||147.07%|
Recent News & Updates
Is There An Opportunity With Sanofi's (EPA:SAN) 47% Undervaluation?Aug 08
We Think Sanofi (EPA:SAN) Can Manage Its Debt With EaseJun 12
Is Sanofi (EPA:SAN) Trading At A 35% Discount?Apr 10
Does Sanofi (EPA:SAN) Have A Healthy Balance Sheet?Feb 14
Is There An Opportunity With Sanofi's (EPA:SAN) 48% Undervaluation?Jan 06
Is Sanofi (EPA:SAN) A Risky Investment?Sep 26
|SAN||FR Pharmaceuticals||FR Market|
Return vs Industry: SAN exceeded the French Pharmaceuticals industry which returned 30.7% over the past year.
Return vs Market: SAN exceeded the French Market which returned 19.1% over the past year.
|SAN Average Weekly Movement||2.5%|
|Pharmaceuticals Industry Average Movement||4.0%|
|Market Average Movement||3.8%|
|10% most volatile stocks in FR Market||9.3%|
|10% least volatile stocks in FR Market||2.0%|
Stable Share Price: SAN is less volatile than 75% of French stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: SAN's weekly volatility (3%) has been stable over the past year.
About the Company
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Sanofi Fundamentals Summary
|SAN fundamental statistics|
Is SAN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SAN income statement (TTM)|
|Cost of Revenue||€13.91b|
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Oct 27, 2023
|Earnings per share (EPS)||6.87|
|Net Profit Margin||18.71%|
How did SAN perform over the long term?See historical performance and comparison